Related Experiment Video

Updated: Dec 7, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.5K

Targeting Cardiac Metabolic Pathways: A Role in Ischemic Management

Awgichew Shewasinad Yehualashet1, Teshome Fentik Belachew2, Zemene Demelash Kifle3

  • 1Pharmacology and Toxicology Unit, Department of Pharmacy, College of Health Sciences, Debre Berhan University, Debre Berhan, Ethiopia.

Vascular Health and Risk Management
|September 28, 2020
PubMed

Insights

Metabolic modulation shows promise for treating ischemic heart disease (IHD) by targeting altered cardiac energy metabolism. Further research into metabolic pathways could improve patient quality of life and IHD management.

Area of Science:

  • Cardiology
  • Metabolic Medicine
  • Biochemistry

Background:

  • Cardiovascular diseases, particularly ischemic heart disease (IHD), are a leading cause of global mortality.
  • Conventional IHD treatments have limitations, and some patients remain refractory to existing therapies.
  • Altered cardiac energy metabolism is implicated in the progression of IHD.

Purpose of the Study:

  • To highlight the therapeutic potential of metabolic modulators for IHD.
  • To review current knowledge on cardiac energy metabolic pathways.
  • To explore novel treatment strategies for improving patient quality of life in IHD.

Main Methods:

  • This review synthesizes existing scientific literature on cardiac metabolism and IHD.
  • It focuses on the role of metabolic pathways in the pathophysiology of IHD.
  • The review examines the evidence supporting metabolic modulation as a treatment strategy.

Main Results:

  • Energy metabolism is fundamentally altered in the progression of IHD.
  • Metabolic pathways represent a promising target for novel IHD therapies.
  • Understanding these pathways is crucial for developing effective treatments.

Conclusions:

  • Metabolic modulation offers a promising avenue for advancing IHD management.
  • Further research into cardiac energy metabolism is warranted to improve therapeutic outcomes.
  • Targeting metabolic pathways may enhance the quality of life for IHD patients.

Keywords:
cardiac energy metabolismischemic heart diseasemetabolic modulationmitochondrial dynamics

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.9K
3D Whole-heart Myocardial Tissue Analysis06:53

3D Whole-heart Myocardial Tissue Analysis

Published on: April 12, 2017

9.1K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
132
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
176
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
94
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.6K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
150
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
158